de Gea Grela A, Martín Carbonero L, Micán R, Bernardino J I, Ramos L, Valencia M E
Mª Eulalia Valencia, Servicio de Medicina Interna, Unidad de VIH, Hospital Universitario La Paz, Madrid, Spain.
Rev Esp Quimioter. 2022 Aug;35(4):378-381. doi: 10.37201/req/013.2022. Epub 2022 May 24.
To analyze the efficacy and tolerability of the strategy to change from rilpivirine (RPV) based regimens to bictegravir / emtricitabine / tenofovir alafenamide (B/F/TAF).
Single-center, observational and retrospective study. Patients who made the change to B/F/TAF before February 2020 were selected, analyzing the results after 24 and 48 weeks. The percentage that remained with an undetectable viral load was determined, as well as the changes in CD4 + lymphocytes, metabolic parameters and renal function.
A total of 42 patients were included. Thirty-two of the 35 patients (91.4%) who completed the 48 weeks of follow-up had an undetectable viral load. The CD4 + lymphocyte count remained stable at 24 and 48 weeks. The response to B/F/TAF was not influenced by the two analogs previously received.
Switching from triple therapy with RPV to B/F/TAF is a safe and effective strategy in real life.
分析从基于利匹韦林（RPV）的治疗方案转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺（B/F/TAF）的策略的疗效和耐受性。
单中心、观察性和回顾性研究。选取2020年2月前转换为B/F/TAF的患者，分析24周和48周后的结果。确定病毒载量仍不可检测的百分比，以及CD4 +淋巴细胞、代谢参数和肾功能的变化。
共纳入42例患者。35例完成48周随访的患者中有32例（91.4%）病毒载量不可检测。CD4 +淋巴细胞计数在24周和48周时保持稳定。对B/F/TAF的反应不受先前接受的两种类似物的影响。
在现实生活中，从含RPV的三联疗法转换为B/F/TAF是一种安全有效的策略。
